Outcomes of patients with myelofibrosis treated with ruxolitinib and anemia-supporting medications. (PubMed, Hematology) - Sep 6, 2026 - "101 patients with baseline hemoglobin <12.0 g/dL initiated an erythropoiesis-stimulating agent (ESA) or danazol <3 months post-enrollment and maintained ESA/danazol ≥3 months; 97% initiated ESAs. This analysis suggests that patients treated with ruxolitinib and anemia-supporting care continued to receive optimal ruxolitinib dosing; spleen-length and symptom response rates in these patients were comparable to the overall JUMP population, the majority of whom did not have anemia. Results support use of anemia-supporting medications with ruxolitinib and may allow maintenance of ruxolitinib dose intensity in patients with myelofibrosis and anemia."
Clinical • Journal • Anemia • Hematological Disorders • Myelofibrosis • Myeloproliferative Neoplasm • Oncology
|
|
Evan Braunstein; Haifa Kathrin Al-Ali; J E Hamer-Maansson; Jennifer Repp; Pankit Vachhani; Valkal Bhatt
|